AnaptysBio
ANAB
131 hedge funds and large institutions have $733M invested in AnaptysBio in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 52 reducing their positions, and 22 closing their positions.
6.42% more ownership
Funds ownership: 100.88% → 107.31% (+6.4%)
4% less funds holding
Funds holding: 136 → 131 (-5)
23% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 22
24% less capital invested
Capital invested by funds: $963M → $733M (-$230M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
37% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.1M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$16.9M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$9.08M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$6.78M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$31.3M |
| 2 |
N
Natixis
Paris,
France
|
-$4.32M |
| 3 |
Walleye Capital
New York
|
-$2.7M |
| 4 |
Goldman Sachs
New York
|
-$2.65M |
| 5 |
EP
Eversept Partners
New York
|
-$2.07M |
ANAB Hedge Fund Activity: Q1 2022 in Review
131 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q1 2022, worth a combined $733M — down 24% from $963M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ANAB and 17 opened new positions — a net loss of 5 holders — while 52 trimmed existing stakes and 33 added.
The largest buyer was Point72 Asset Management, adding an estimated $32.1M. The largest seller was Frazier Management, exiting entirely with an estimated $31.3M sold.
- 131 institutional investors held AnaptysBio (ANAB) as of Q1 2022, down from 136 in Q4 2021.
- Funds reported $733M of AnaptysBio stock for Q1 2022, down 24% quarter-over-quarter.
- 17 funds opened new AnaptysBio positions in Q1 2022 and 22 closed out, a net change of -5 holders.
- The largest AnaptysBio buyer in Q1 2022 was Point72 Asset Management, an estimated $32.1M added.
- The largest AnaptysBio seller in Q1 2022 was Frazier Management, an estimated $31.3M sold.
Based on aggregated 13F filings for Q1 2022.